Our latest thinking on industry-specific issues relevant to our market.
Our Featured Insight
Explore our three-step framework for reducing confirmation bias in your organizational decision-making.
Alternative lenders offer attractive financing prospects for small businesses unable to secure traditional lending. Did pandemic shutdowns change that?
Of the two broad policy levers that influence economic growth – fiscal and monetary stimulus – which is the better driver of real growth?
A global pandemic may have created a new opportunity to rethink the role of banks in the economy, drawing from lessons of the last decade.
Can an issue as complex as a country’s infant mortality rate (IMR) provide insights for its national health? It depends on the data.
With COVID pushing banks and traditional lenders to restrict previous lending criteria, many small businesses no longer qualify for loans that would grant them much-needed financial support. Some fintechs may be able to fill this gap.
Major industries have responded to the COVID crisis in ways both similar and disparate. Here’s how to compare their different responses.
The effects of the coronavirus pandemic on the stock market may give some early indications of long-term trends for investment.
On the cusp of a new decade, how can we better understand the human impact of the the coming-of-age of AI/ML, including the changing role for programmers and data scientists?
Physician-owned medical practices are on the decline, due in part to mounting reimbursement pressures and overhead costs. Independent physicians can see demonstrable improvements to their private practice’s revenues and profits with efficiency-minded billing processes.
The Growing Influence of Alternative Lenders: More Options for Small Businesses, New Competition for Large Banks
What changes might result from the increased prevalence of alternative lenders in the context of small business lending, a space large banks mostly avoid?
In an increasingly saturated market, how can offering a rewards credit card to existing clients remain a viable value proposition?
How could anonymized patient data be used to develop an approach for identifying procedures likely to be considered low-value care?
Copyright © 2019 FischerJordan. All Rights Reserved.
DISCLAIMER - This content is for informational purposes only. You should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on our Site constitutes a solicitation, recommendation, endorsement, or offer by FischerJordan or any third party service provider to buy or sell any securities or other financial instruments in this or in in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction.
All Content on this site is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the Site constitutes professional and/or financial advice, nor does any information on the Site constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. FischerJordan is not a fiduciary by virtue of any person’s use of or access to the Site or Content. You alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other Content on this Site before making any decisions based on such information or other Content. In exchange for using the Site, you agree not to hold FischerJordan, its affiliates or any third party service provider liable for any possible claim for damages arising from any decision you make based on information or other Content made available to you through the Site.